Next-generation Sequencing Market is Expected to Witness a Robust CAGR of 18.1% Over The Forecast Period 2017–2025 | Explore By Global Players Qiagen N.V., BioMerieux S.A., Thermo Fisher Scientific Inc., Beijing Genomics Co. Ltd., Illumina, Inc.

Next Generation Sequencing (NGS) is a powerful, flexible, and indispensable biological tool that is used in several areas of biological study. NGS technologies help in generating genome-wide sequence data in a couple of days. These technologies are highly parallelized allowing to sequence thousands to millions of molecules at the same time. The main advantage of these platforms is determination of the sequenced data from amplified single DNA fragments, avoiding the need for cloning of DNA fragments.

NGS has large number of applications, enabling rapid technological advances across several fields in biological science. The technology has enabled researchers to gain significant knowledge in public health studies and epidemiology, to sequence viruses and bacteria and help detect causes that may contribute to virulence. Furthermore, in gene expression research, next generation sequencing of RNA replace microarray analysis, allowing researchers to see RNA expression sequence. This RNA sequencing can provide information on entire transcriptome in one analysis, irrespective of any previous knowledge of genetic sequence.

Request For Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/158

Key players in the next generation sequencing market include,

1. Thermo Fisher Scientific Inc.
2. Agilent Technologies, Inc.
3. BioMerieux S.A.
4. F. Hoffmann-La Roche Ltd
5. Qiagen N.V.
6. Illumina, Inc.
7. Oxford Nanopore Technologies
8. Beijing Genomics Co. Ltd.

Rising demand for early detection of cancer and infectious diseases to drive growth of the NGS market

The chances of successful treatment increase when cancer and infectious diseases are detected at the early stage. One of the major factors that drive growth of the next generation sequencing market is the rising prevalence of cancer and other infectious diseases. According to the World Health Organization (WHO), in 2012, new cases of cancer was around 14 million and the incidence is estimated to increase to 70% by 2030.

As per statistics published by National Cancer Institute (NCI), in 2016, 1,685,210 new cases of cancer were diagnosed in the U.S. alone. In 2015, WHO reported 8.8 million deaths occurred due to cancer. According to American Cancer Society (ACS), in 2017, around 161,360 cases of prostate cancer were reported in the U.S alone. ACS, in 2015, also reported 4.5 million new cancer cases in China and the number is expected to increase to 7.6 Mn by 2020. Morbidity cases in tuberculosis, salmonella, and meningococcal disease was as high as 90,000 in the U.S. in 2016. Therefore, increasing demand for early diagnosis of cancer and infectious diseases, to aid in better outcome, is in turn expected to aid in growth of the market over the forecast period.

Increasing demand for DNA testing

Demand for DNA testing is increasing, due to advancements in whole genome and exome sequencing procedures, faster results and cost effectives of the process as compared to genotyping based DNA microarray. In December, 2014, the first commercial sequencer, MinIon, using Nanopore technology was introduced by Oxford Nanopore Technologies. The sequencer identifies DNA by measuring the changes in the electrical conductivity generated DNA strands passed through biological pore. This technology enabled the detection of outbreaks such as Zika virus. Furthermore, GenapSys, a U.S.-based developer of DNA sequencing technologies for applied genomic testing, introduced GENIUS sequencer, which can sequence DNA anywhere.

Detailed Segmentation:

Global Next Generation Sequencing Market, By Technology:

• Whole Genome Sequencing
• Whole Exome Sequencing
• RNA Sequencing
• Targeted Re-sequencing
• Others

Global Next Generation Sequencing Market, By Application:

• Drug Discovery
• Personalized Medicine and Genetic Screening
• Disease Diagnosis
• Agriculture and Animal Research
• Others

Global Next Generation Sequencing Market, By End User:

• Hospital
• Research Centers
• Pharma and Biotech Firms
• Others

Global Next Generation Sequencing Market, By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Request For Customization of This Exclusive Report @ https://www.coherentmarketinsights.com/insight/request-customization/158

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.